214 related articles for article (PubMed ID: 33647772)
1. Development of a novel, fully human, anti-PCSK9 antibody with potent hypolipidemic activity by utilizing phage display-based strategy.
Xu M; Lei G; Chen M; Wang K; Lv W; Zhang P; Hu T; Gao J; Lu C; Mei Y; Xu Z; Bai Z; Hu H; Jiang Y; Tan S
EBioMedicine; 2021 Mar; 65():103250. PubMed ID: 33647772
[TBL] [Abstract][Full Text] [Related]
2. Selection and characterization of human PCSK9 antibody from phage displayed antibody library.
Cao Y; Yang H; Zhou X; Mao H; Gao T; Hu Z; He L; Pan F; Guo Z
Biochem Biophys Res Commun; 2015 Aug; 463(4):712-8. PubMed ID: 26056005
[TBL] [Abstract][Full Text] [Related]
3. Construction and application of a human scFv phage display library based on Cre‑LoxP recombination for anti‑PCSK9 antibody selection.
Dong Y; Meng F; Wang Z; Yu T; Chen A; Xu S; Wang J; Yin M; Tang L; Hu C; Wang H; Cai J
Int J Mol Med; 2021 Feb; 47(2):708-718. PubMed ID: 33416098
[TBL] [Abstract][Full Text] [Related]
4. A proprotein convertase subtilisin-like/kexin type 9 (PCSK9) C-terminal domain antibody antigen-binding fragment inhibits PCSK9 internalization and restores low density lipoprotein uptake.
Ni YG; Condra JH; Orsatti L; Shen X; Di Marco S; Pandit S; Bottomley MJ; Ruggeri L; Cummings RT; Cubbon RM; Santoro JC; Ehrhardt A; Lewis D; Fisher TS; Ha S; Njimoluh L; Wood DD; Hammond HA; Wisniewski D; Volpari C; Noto A; Lo Surdo P; Hubbard B; Carfí A; Sitlani A
J Biol Chem; 2010 Apr; 285(17):12882-91. PubMed ID: 20172854
[TBL] [Abstract][Full Text] [Related]
5. Generation of a Novel High-Affinity Antibody Binding to PCSK9 Catalytic Domain with Slow Dissociation Rate by CDR-Grafting, Alanine Scanning and Saturated Site-Directed Mutagenesis for Favorably Treating Hypercholesterolemia.
Bai Z; Xu M; Mei Y; Hu T; Zhang P; Chen M; Lv W; Lu C; Tan S
Biomedicines; 2021 Nov; 9(12):. PubMed ID: 34944600
[TBL] [Abstract][Full Text] [Related]
6. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Single Domain Antibodies Are Potent Inhibitors of Low Density Lipoprotein Receptor Degradation.
Weider E; Susan-Resiga D; Essalmani R; Hamelin J; Asselin MC; Nimesh S; Ashraf Y; Wycoff KL; Zhang J; Prat A; Seidah NG
J Biol Chem; 2016 Aug; 291(32):16659-71. PubMed ID: 27284008
[TBL] [Abstract][Full Text] [Related]
7. Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9.
Jang HD; Lee SE; Yang J; Lee HC; Shin D; Lee H; Lee J; Jin S; Kim S; Lee SJ; You J; Park HW; Nam KY; Lee SH; Park SW; Kim JS; Kim SY; Kwon YW; Kwak SH; Yang HM; Kim HS
Eur Heart J; 2020 Jan; 41(2):239-252. PubMed ID: 31419281
[TBL] [Abstract][Full Text] [Related]
8. LDL-R promoting activity of peptides derived from human PCSK9 catalytic domain (153-421): design, synthesis and biochemical evaluation.
Alghamdi RH; O'Reilly P; Lu C; Gomes J; Lagace TA; Basak A
Eur J Med Chem; 2015 Mar; 92():890-907. PubMed ID: 25679794
[TBL] [Abstract][Full Text] [Related]
9. Activation of Adiponectin Receptor Regulates Proprotein Convertase Subtilisin/Kexin Type 9 Expression and Inhibits Lesions in ApoE-Deficient Mice.
Sun L; Yang X; Li Q; Zeng P; Liu Y; Liu L; Chen Y; Yu M; Ma C; Li X; Li Y; Zhang R; Zhu Y; Miao QR; Han J; Duan Y
Arterioscler Thromb Vasc Biol; 2017 Jul; 37(7):1290-1300. PubMed ID: 28546220
[TBL] [Abstract][Full Text] [Related]
10. An anti-PCSK9 antibody reduces LDL-cholesterol on top of a statin and suppresses hepatocyte SREBP-regulated genes.
Zhang L; McCabe T; Condra JH; Ni YG; Peterson LB; Wang W; Strack AM; Wang F; Pandit S; Hammond H; Wood D; Lewis D; Rosa R; Mendoza V; Cumiskey AM; Johns DG; Hansen BC; Shen X; Geoghagen N; Jensen K; Zhu L; Wietecha K; Wisniewski D; Huang L; Zhao JZ; Ernst R; Hampton R; Haytko P; Ansbro F; Chilewski S; Chin J; Mitnaul LJ; Pellacani A; Sparrow CP; An Z; Strohl W; Hubbard B; Plump AS; Blom D; Sitlani A
Int J Biol Sci; 2012; 8(3):310-27. PubMed ID: 22355267
[TBL] [Abstract][Full Text] [Related]
11. microRNA-483 ameliorates hypercholesterolemia by inhibiting PCSK9 production.
Dong J; He M; Li J; Pessentheiner A; Wang C; Zhang J; Sun Y; Wang WT; Zhang Y; Liu J; Wang SC; Huang PH; Gordts PL; Yuan ZY; Tsimikas S; Shyy JY
JCI Insight; 2020 Dec; 5(23):. PubMed ID: 33119548
[TBL] [Abstract][Full Text] [Related]
12. In vitro selection generates RNA aptamer that antagonizes PCSK9-LDLR interaction and recovers cellular LDL uptake.
Ando T; Yamamoto M; Yokoyama T; Horiuchi D; Kawakami T
J Biosci Bioeng; 2021 Mar; 131(3):326-332. PubMed ID: 33177004
[TBL] [Abstract][Full Text] [Related]
13. Serum proprotein convertase subtilisin/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation.
Tavori H; Fan D; Blakemore JL; Yancey PG; Ding L; Linton MF; Fazio S
Circulation; 2013 Jun; 127(24):2403-13. PubMed ID: 23690465
[TBL] [Abstract][Full Text] [Related]
14. Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms.
Tavori H; Giunzioni I; Predazzi IM; Plubell D; Shivinsky A; Miles J; Devay RM; Liang H; Rashid S; Linton MF; Fazio S
Cardiovasc Res; 2016 May; 110(2):268-78. PubMed ID: 26980204
[TBL] [Abstract][Full Text] [Related]
15. A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates.
Chan JC; Piper DE; Cao Q; Liu D; King C; Wang W; Tang J; Liu Q; Higbee J; Xia Z; Di Y; Shetterly S; Arimura Z; Salomonis H; Romanow WG; Thibault ST; Zhang R; Cao P; Yang XP; Yu T; Lu M; Retter MW; Kwon G; Henne K; Pan O; Tsai MM; Fuchslocher B; Yang E; Zhou L; Lee KJ; Daris M; Sheng J; Wang Y; Shen WD; Yeh WC; Emery M; Walker NP; Shan B; Schwarz M; Jackson SM
Proc Natl Acad Sci U S A; 2009 Jun; 106(24):9820-5. PubMed ID: 19443683
[TBL] [Abstract][Full Text] [Related]
16. Regions of conformational flexibility in the proprotein convertase PCSK9 and design of antagonists for LDL cholesterol lowering.
Kirchhofer D; Burdick DJ; Skelton NJ; Zhang Y; Ultsch M
Biochem Soc Trans; 2020 Aug; 48(4):1323-1336. PubMed ID: 32794575
[TBL] [Abstract][Full Text] [Related]
17. A transient amphipathic helix in the prodomain of PCSK9 facilitates binding to low-density lipoprotein particles.
Sarkar SK; Foo ACY; Matyas A; Asikhia I; Kosenko T; Goto NK; Vergara-Jaque A; Lagace TA
J Biol Chem; 2020 Feb; 295(8):2285-2298. PubMed ID: 31949048
[TBL] [Abstract][Full Text] [Related]
18. Novel strategies to target proprotein convertase subtilisin kexin 9: beyond monoclonal antibodies.
Seidah NG; Prat A; Pirillo A; Catapano AL; Norata GD
Cardiovasc Res; 2019 Mar; 115(3):510-518. PubMed ID: 30629143
[TBL] [Abstract][Full Text] [Related]
19. In silico Screening of Chemical Libraries to Develop Inhibitors That Hamper the Interaction of PCSK9 with the LDL Receptor.
Min DK; Lee HS; Lee N; Lee CJ; Song HJ; Yang GE; Yoon D; Park SW
Yonsei Med J; 2015 Sep; 56(5):1251-7. PubMed ID: 26256967
[TBL] [Abstract][Full Text] [Related]
20. Development of a PCSK9-targeted nanoparticle vaccine to effectively decrease the hypercholesterolemia.
Fang Q; Lu X; Zhu Y; Lv X; Yu F; Ma X; Liu B; Zhang H
Cell Rep Med; 2024 Jun; 5(6):101614. PubMed ID: 38897173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
